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SUMMARY: Increased podosome formation due to E527K hyperactive SRC results in 
thrombocytopenia, myelofibrosis, bleeding and bone pathologies 
 
ABSTRACT (237/250) 
The Src family kinase (SFK) member SRC is a major target in drug development because 
it is activated in many human cancers, yet deleterious SRC germline mutations have not 
been reported. We used genome sequencing and Human Phenotype Ontology patient 
coding to identify a gain-of-function mutation in SRC causing thrombocytopenia, 
myelofibrosis, bleeding and bone pathologies in nine cases. Modeling of the E527K 
substitution predicts loss of SRC’s self-inhibitory capacity, which we confirmed with in 
vitro studies showing increased SRC kinase activity and enhanced Tyr419 
phosphorylation in COS7 cells overexpressing E527K SRC. The active form of SRC 
predominates in patients’ platelets, resulting in enhanced overall tyrosine 
phosphorylation. Patients with myelofibrosis have hypercellular bone marrow with 
trilineage dysplasia and their stem cells grown in vitro form more myeloid and 
megakaryocyte (MK) colonies than control cells. These MKs generate platelets which are 
dysmorphic, low in number, highly variable in size and with a paucity of α-granules. 
Over-active SRC in patient-derived MKs causes a reduction in proplatelet formation, 
which can be rescued by SRC kinase inhibition. Stem cells transduced with lentiviral 
E527K SRC form MKs with a similar defect and enhanced tyrosine phosphorylation 
levels. Patient-derived and E527K-transduced MKs show Y419 SRC-positive stained 
podosomes that induce altered actin organization. Expression of mutated src in 
zebrafish recapitulates patients’ blood and bone phenotypes. Similar studies of platelets 
and MKs may reveal the mechanism underlying the severe bleeding frequently observed 
in cancer patients treated with next-generation SFK inhibitors. 
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INTRODUCTION 
The Rous sarcoma virus (RSV), via its v-src viral gene lacking the codon for the 
tyrosine(Y)-527 self-inactivation residue, was described in the mid-20th century as causing 
tumor growth in chickens (1, 2). v-Src increased phosphotyrosine levels in cellular proteins 
within RSV-transformed cells (3) and induced actin-based dynamic protrusions of the plasma 
membrane, named podosomes and invadosomes (4,5). The highly similar proto-oncogene 
tyrosine-protein kinase SRC (or c-Src) is a non-receptor tyrosine kinase protein that  is encoded 
by the SRC gene. A somatic truncating mutation at SRC residue 531 has been detected in 
human colon cancer and also results in SRC activation (6). Of all Src family kinases (SFKs), 
SRC is the most frequently implicated in cancer and various SFK inhibitors are in clinical trials 
(7, 8). Dasatinib, Bosutinib and Ponatinib were developed as next-generation inhibitors against 
Bcr-Abl to treat chronic myeloid leukemia (CML) and other targets (including SFKs) (9). 
Although these drugs are not SRC-specific, it is remarkable that approximately 10-40% of CML 
cases treated develop hematological side-effects, including severe bleeding which is 
disproportionate to the reduction in platelet counts (9, 10). Pathogenic germline mutations in 
SRC, however, have never been described in humans.  
The highest SRC protein levels are found in platelets (11) and brain (12), with only 
moderate expression in other tissues. Remarkably, Src knockout mice have no detectable brain 
phenotype, no bleeding symptoms and a normal platelet count (13). Most homozygous mice die 
within the first weeks of birth and those which survive present only with impaired osteoclast 
function, osteopetrosis and a failure of incisors to erupt. Over the last three decades, several 
activation pathways in platelets have been studied that are regulated by different SFKs. In both 
mice and humans, platelet signalling events downstream of platelet integrins, G-protein coupled 
receptors for agonists and the receptor for VWF are described as being dependent on SRC 
(14). Here, we show that a germline gain-of-function SRC mutation leads to thrombocytopenia, 
myelofibrosis, bleeding, platelet dysfunction with abnormal α-granules and bone pathologies. 
 
RESULTS 
Statistical analysis of genetic and phenotypic data 
We studied a three-generation pedigree with a dominant inheritance of bleeding with 
fatal consequences for one of the nine cases. Microscopic inspection of the blood film showed a 
reduced number of platelets of which about 10-30% have a grayish appearance due to a lack of 
α-granules (Fig. 1A, table 1). Five cases presented prematurely with myelofibrosis 
accompanied by enlargement of their spleens (table 1). Three cases underwent splenectomy, 
which did not correct the platelet count or their atypical morphology. Cases in this pedigree also 
have extensive bone pathologies with edentulism before the third decade and mild 
dysmorphism characterised by large forehead, ocular hypotelorism, deep-set eyes and a wide-
nostriled nose (table 1). The clinical and laboratory phenotypes of three cases were coded with 
Human Phenotype Ontology (HPO) terms (15), including terms relating to platelet morphology 
(Fig. 1C). Mutations in known thrombocytopenia genes were absent, prompting us to subject 
DNA samples from two cases (Fig. 1A) to genome sequencing. After filtering by alternate allele 
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frequency in reference collections and selecting variants predicted to affect translation, we 
determined that these two cases shared 67 plausible causal variants in 67 candidate genes. 
Building on recent approaches for HPO-based differential diagnosis (16) and gene prioritisation 
(17), we ranked these genes based on the mean phenotypic similarity between the three cases 
who underwent HPO coding and HPO terms derived from the OMIM (Online Mendelian 
Inheritance in Man) and MGI (Mammalian Genome Informatics) databases. This approach 
ranked SRC at the top of the 31 candidate genes for which term data were available (Fig. 1B). 
SRC encodes the proto-oncogene tyrosine-protein kinase SRC and knock-out of its highly 
homologous orthologue in mice showed no bleeding and apparently normal platelets (13). 
However, the Src-/- mouse presented with increased bone density (osteopetrosis), which is the 
opposite of the osteoporosis of the pedigree cases (18). The proximity of these two related but 
opposing terms in the ontologies enabled SRC to score highest (Fig. 1, B and C). The SRC 
variant had a Combined Annotation-Dependent Depleted (CADD) (19) phred score of 34 (Fig. 
1D), and was amongst only 24 of the 67 candidates to be unobserved in 61,486 unrelated 
subjects from the ExAC database and 2,974 further subjects from our in-house collection. 
Inspection of the results of sequencing of RNA from blood stem and progenitor cells, including 
MKs (20), showed that the SRC transcript ranked amongst the highest according to the 
probability of being over-expressed in MKs compared to the other seven cell types (posterior 
probability=0.47) (Fig. 1E). Finally, the SRC variant c.1579G>A was found by Sanger 
sequencing to co-segregate with the disease phenotype in three additional cases and was 
absent from unaffected relative 21 (DNA from the remaining four cases was not available) (p = 
0.03125) (fig. S1). The four independent sources of evidence thus established the variant 
coding glutamic acid (E) 527 lysine (K) in SRC’s kinase domain as the primary causative 
candidate for this novel syndrome. 
 
Platelet phenotypes and functional effect of the E527K SRC variant  
Morphological examination of platelets from three cases by electron microscopy (EM) 
shows heterogeneous sized platelets (Fig. 2, A and B and fig. S2) with features of Gray Platelet 
Syndrome (GPS) as they have a paucity of α-granules (Fig. 2C) and abundant vacuoles. This 
was confirmed by quantitative blotting showing reduced levels of α-granule-stored von 
Willebrand factor (VWF) and thrombospondin 1 (TSP1) (Fig. 2D). Patients with classic GPS 
caused by recessive mutations in NBEAL2 (21) have a bleeding disorder because the cargo of 
α-granules is essential for maintaining hemostasis. GPS patients and Nbeal2-/- mice show 
premature myelofibrosis leading to extramedullary formation of blood cells and splenomegaly. 
This fibrosis is likely caused by pro-inflammatory MKs (22). However, some other features of 
our cases are not typical for classic GPS, such as presence of both abnormally large and small 
platelets without any type of granules and lacking internal membranes (Fig. 2A and fig. S2). As 
expected, activation with collagen or the more potent rattlesnake venom convulxin causes 
appearance of the α-granules’ membrane protein P-selectin (CD62P) on the platelet outer-
membrane. However, in keeping with the EM and blot-ascertained paucity of α-granule 
proteins, the amounts of P-selectin after activation were significantly reduced (collagen: p = 
1.09 x 10-7; convulxin: p = 2.65 x 10-3) (Fig. 2E and fig. S3). 
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The mutated residue E527 is three amino acids upstream from Y530 in the C-terminal 
tail of the SRC kinase domain (Fig. S4). The negatively charged residue is conserved for SRC 
across 100 vertebrate species (PhyloP (23) p = 7.48 x 10-5) and also in the remaining seven 
SFKs. Differential phosphorylation between Y530 and Y419 regulates switching of SRC 
between inactive and active states. SRC is predominantly in the former state because Y530 
mediates an interaction with the SH2 domain, which effectively folds SRC into a closed 
inaccessible bundle. Autophosphorylation of Y419 enforces an active configuration by 
displacing it from the kinase cleft, allowing substrates to gain access (24, 25). The three-
dimensional structure of SRC reveals, interestingly, that the C-terminal tail (denoted here as the 
Velcro-strap) carries an extremely high temperature factor, indicating high flexibility (red color in 
Fig. 2F and fig. S5). SRC is maintained in the inactive state because this Velcro-strap stabilizes 
the SH2 domain through electrostatic interactions between residues E527 with R159 and of 
Y530 with the side-chains of R158, R178 and main-chain atoms of T181 and E182 (Fig. 2F, 
left). Modelling of the consequences of the mutation at residue 527 indicates that the favored 
interaction with R159 may be lost and is possibly replaced by an alternative electrostatic 
interaction with the neighboring negatively charged glutamic and aspartic acids at residues 520 
or 521, respectively (Fig. 2F, right). This assumed reconfiguration caused by the mutation may 
favor SRC to adopt a constitutively active state. We challenged this hypothesis by testing the 
wild-type (WT) and mutant forms with the Phosp3D program (26), which predicted Y530 
phosphorylation only for WT SRC. An in vitro kinase assay using GST-tagged SRC proteins 
indeed show a higher kinase activity for E527K compared to WT SRC (p = 2.2 x 10-16) that can 
partially be inhibited by addition of SRC inhibitor-1 (Fig. 2G, left). Immunoblot analysis of these 
GST-tagged SRC proteins confirms the differential phosphorylation pattern between WT and 
E527K SRC using specific Y530 and Y419 antibodies that recognize inactive and active SRC, 
respectively (Fig. 2G, right). 
 
E527K SRC expression in patients’ platelets and transfected cells 
The predicted consequence of the E527K mutation on SRC’s function was explored 
using SRC activity-specific antibodies. Immunoblot analyses of platelets show increased levels 
of active SRC in mutation carriers versus controls after accounting for global genotype and 
antibody effects (p = 9.42 x 10-15) and irrespective of the activation state of the platelets (Fig. 3A 
and supplementary materials). Platelets from unaffected pedigree member 21 could only be 
tested under non-activated conditions but show comparable SRC levels to those in control 
platelets (Fig. 3A). SRC activation in platelets of affected cases is accompanied by increased 
overall tyrosine phosphorylation irrespective of the platelet activation status (Fig. 3B and fig. 
S6). These platelet abnormalities are independent of the bone marrow changes, as case 19 has 
no myelofibrosis. The expression of three other SFK members (FGR, FYN and YES) was 
normal in platelets of the cases (fig. S7). 
Platelets from cases are assumed to contain both WT and mutant SRC. To determine 
the activation state of mutant SRC in the absence of WT, we turned to COS-7 cells that do not 
express SRC protein at detectable levels. We transfected the cells with mutant, WT and a 
mixture of mutant and WT protein to simulate a homozygous WT, homozygous mutant and 
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heterozygous genotype. Reactivity of the antibody against Y530 was negatively associated with 
the genotype (p = 2.39 x 10-6) while reactivity of the antibody against Y419 was positively 
associated with the genotype (p = 0.014) (Fig. 3C, left). In cells harboring the mutant nearly all 
SRC reacted with the antibody against Y419 while reactivity with the antibody against Y530 was 
negligible (Fig. 3C, right and supplementary materials), as shown previously for activating 
Y527F mutant chicken SRC (corresponding to residue 530 in humans) (27). Interestingly, co-
transfection of WT and mutant protein was sufficient to induce substantially increased Y419 
levels (Fig. 3C). Transfections of WT and mutant SRC in the presence of SRC inhibitor-1 
resulted in significantly lower Y419 SRC levels for mutant transfected cells (p = 7.78 x 10-5) 
while no changes were observed for WT transfected cells (Fig. 3D). This is in agreement with 
the previously described observation that autophosphorylation and dephosphorylation of Y419 
are directly correlated with the level of SRC activity (28). 
 
Defective megakaryopoiesis due to E527K SRC 
Of the eight SFKs (7), SRC exhibits the strongest over-expression in MKs relative to 
other blood cell progenitors (table S1). Detailed examination of several bone marrow biopsy 
samples from case 35 showed trilineage dysplasia with a high number of MKs having dysplastic 
features and hypo-lobulated nuclei (table 1), which are hallmarks of immaturity. Thrombopoietin 
(TPO) is the pivotal growth and differentiation factor for MKs and its receptor MPL is present on 
blood stem cells, MKs and platelets (29). Platelets from SRC-mutant cases with myelofibrosis 
express normal MPL levels (fig. S8) but their plasma contains elevated TPO levels (Fig. 4A). 
Elevated plasma TPO levels are exceptional and characteristic for MPL-inactivating mutations 
which cause congenital amegakaryocytic thrombocytopenia (CAMT) (30). However, 
hematopoietic stem cells from CAMT cases cannot form MKs in the presence of TPO while 
SRC-mutant blood stem cells produced more MK but also more myeloid (GEMM) colonies (Fig. 
4B) than control cells, which is in agreement with the bone marrow biopsy findings. Blood stem 
cells of three pedigree cases, when cultured with TPO, formed numerous immature MKs with 
almost no proplatelets (Fig. 4C). Proplatelet formation for unaffected Case 21 was normal (Fig. 
4C). Interestingly, addition of the SRC inhibitor-1 starting from culture day 1 could partially 
restore proplatelet formation for affected Case 31 while it had no discernible effect on control or 
unaffected cells (Fig. 4C). Immunostaining for active SRC (Y419) of day 12 MKs showed a 
significantly increased number of positively-stained MKs for the patients compared to control 
MKs that only showed a very weak perinuclear signal (Fig. 4D). In contrast, staining of E527K 
MKs showed evidence of active SRC located in rosette-like structures (Fig. 4D). The 
oncoprotein v-Src is known to alter the actin cytoskeleton and induce focal cell adhesions and 
podosomes that induced changes in cell morphology and migration (6, 31). Staining of 
fibroblasts from patient 35 indeed also showed active SRC staining near focal adhesions, which 
is not observed in control cells (fig. S9). 
 To further ascertain the effect of E527K on megakaryopoiesis, blood stem cells from 
normal donors were transduced with lentiviral vectors that overexpress GFP, WT and mutant 
SRC. Immunoblot analysis of differentiated MKs showed high levels of Y530 and Y419 under 
WT and mutant transduced conditions, respectively (Fig. 4E). As observed in platelets, 
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increased overall tyrosine phosphorylation was present in mutant MKs while in the WT only a 
single band was present that likely corresponds to Y530 SRC (Fig. 4E). Ploidy analysis of the 
transduced MKs showed weak evidence of an increased number of immature (2N) MKs in 
E527K overexpression conditions compared to WT (Fig. 4F and fig. S10). Quantification of 
proplatelet formation showed significantly reduced proplatelet-forming MKs for E527K 
transduced conditions compared to WT (Fig. 4G and fig S11). Immunostaining for total or Y419 
SRC was weak for non-transduced cells (fig. S12) while strong staining was present for the 
SRC-transduced conditions. Mutant-transduced MKs recapitulated the presence of rosette-like 
structures that partially co-stain with filamentous actin, which were absent from WT (Fig. 4H and 
fig. S12). In general, E527K-transduced MKs have a strongly altered actin organisation even 
when they have a tendency to form proplatelets (fig. S12C). Cortactin (or cortical-actin binding 
protein) is normally located in the cytoplasm but upon tyrosine-phosphorylated induced 
activation, it locates to podosomes where it promotes actin reorganisation (32). Staining of the 
lentiviral transduced MKs for cortactin showed similar types of rosette structures in E527K-
transduced MKs while WT-transduced cells have significantly reduced numbers of cortactin-
positive podosomes for different time points during MK differentiation (fig. S13).   
 
Blood and bone phenotypes in Src-E525K overexpression zebrafish 
We injected zebrafish src mRNA containing the E525K mutation (corresponding to E527K in 
humans) or the WT sequence to study the formation of blood cells and bone. Overexpression of 
mutant src resulted in abnormal early primitive hematopoiesis between 16 and 24 hours post 
fertilization (hpf) with a migration defect of GATA1-positive stem cells (fig. S14). Mutant 
embryos at 3 days post fertilization (dpf) have normal formation of red cells (fig. S14) while 
thrombocyte numbers appear to be reduced (Fig. 5A). Counting of thrombocytes by flow 
cytometry showed 493 versus 852 CD41+ thrombocytes in 10 pooled mutant src and control 
embryos respectively. Immunoblot analysis of 15 embryo lysates showed reduced levels of 
GFP-positive thrombocytes though quantification analysis of a triplicate injection experiment 
showed only a trend for lower GFP levels for E525K mutant embryos that did not reach 
statistical significance (Fig 5A). SRC levels did not differ between buffer (control) or RNA- 
injected embryos (Fig. 5A), which probably indicates that the RNA overexpression is not 
detectable at 3 dpf. E525K src-injected embryos in the presence of SRC inhibitor-1 had lower 
tyrosine phosphorylation levels and higher GFP levels compared to embryos without the 
inhibitor. Interestingly, E525K src -injected embryos at 5 dpf have significantly smaller bones 
compared to WT-injected embryos and this change was absent when the SRC inhibitor-1 was 
added to the fish water (Fig. 5B). Splice morpholino-induced src-depleted embryos show 
normal thrombocyte formation but have larger bones (fig. S15).   
 
DISCUSSION 
Inherited thrombocytopenia (IT) with early onset myelofibrosis was the clinical diagnosis 
for cases of the presented pedigree upon referral for genetic studies. ITs are a heterogeneous 
group of diseases caused by at least 20 different genes that cause alterations in transcription 
regulation, TPO signalling, cytoskeletal organization, granule trafficking and receptor signalling 
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in patients’ MKs (33), which result in lower platelet counts with either larger, smaller or normal 
sized platelets. None of the previously described ITs matched entirely with the platelet 
phenotype in our cases. They were characterised by presence of both unusually small and large 
platelets, of which some have a GPS-like phenotype, elevated plasma TPO levels, increased 
numbers of MKs in the marrow and differentiated in vitro trilineage dysplasia and myelofibrosis. 
All known genetic causes for ITs were excluded (34). A detailed clinical description using HPO 
terms (34) that also included non-hematological terms to describe the mild bone defects in 
cases of this pedigree, such as decreased bone mineral density, fractures and tooth loss, 
assisted in the unique gene discovery approach used to discover the cause of this new 
syndrome. Our discovery has been made possible by comparison of HPO terms of the cases 
with Mouse Phenotype Ontology-mapped HPO terms from 7,541 strains. Though Src-deficient 
mice have normal platelets, they were described as manifesting with 8 terms that overlapped 
with the HPO terms for the human cases, including abnormality of teeth and abnormal bone 
mineral density (13). In addition, genome data analysis was empowered by making use of a 
large cohort of patients with inherited bleeding and platelet disorders (34). The selection of the 
SRC gene variant E527K as the most likely candidate was also aided by using the Blueprint 
blood cell progenitor RNA-seq dataset (20). 
The E527K variant was predicted by modeling and shown by in vitro studies to result in a 
constitutively active kinase that causes increased overall tyrosine phosphorylation levels in 
platelets and megakaryocytes. As SRC was not previously expected to play a role in 
megakaryopoiesis and platelet formation, we performed extensive studies using patient-derived 
and E527K lentiviral transduced stem cells. These data show that active E527K SRC results in 
more immature MKs and a defect in proplatelet formation with extensive alterations in the actin 
cytoskeleton and podosome structures when adhered to fibrinogen. As found for constitutively 
active v-Src-transformed cells, these actin-based dynamic protrusions of the plasma membrane 
were typically present at sites where the cells adhere to the extracellular matrix (ECM) (5, 6) but 
they also mediate cell migration (35). Podosomes have since been studied as dynamic F-actin-
based adhesion spots associated with motile cells of the myeloid lineage such as macrophages 
(36), dendritic cells (37) and megakaryocytes (38). These studies were all conducted using 
blood cells from Wiskott-Aldrich syndrome (WAS) patients and showed reduced podosome 
formation and cell motility. WAS is an X-linked disorder characterized by eczema, 
microthrombocytopenia and severe immunodeficiency due to WAS gene mutations. Sabri et al 
(38) found that Was knockout mice have MKs that almost completely lack actin-rich podosomes 
after interaction with the bone matrix component collagen I, which results in enhanced 
proplatelet formation and MKs that shed platelets within the bone marrow space (38). WAS 
codes for a protein that regulates the actin cytoskeleton via the Arp2/3 complex. Interestingly, 
WAS is known to be tyrosine phosphorylated though it is unclear whether this actually 
influences WAS activities (39). It was recently shown by in vitro studies that podosomes in 
normal MKs can degrade the ECM and are therefore predicted to have a pivotal role in MK 
motility and ECM remodelling, including activities such as extension of proplatelet arms across 
the membrane of a sinusoidal vessel (40). We found no evidence of proplatelet formation within 
the bone marrow of our cases and observe the opposite phenotype of increased podosome 
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formation and reduced proplatelet formation, which might indicate that the exact number or life 
time of podosomes might be critical for proplatelet formation. Podosomes have also been 
described in osteoclasts (41) and have been shown to precede bone resorption (42). The 
opposite bone phenotypes of osteopetrosis in Src-deficient mice and osteoporosis in our cases 
might also be due to the critical balance of podosome numbers. 
Finally, we have tried to mimic this novel disorder in a zebrafish model. Though we 
clearly observed the opposite bone defect in Src-depleted versus E525K-Src-injected embryos 
with significantly larger and smaller bones, respectively, the blood cell phenotype is less 
obvious. However, this might be due to the fact that though the molecular control of primitive 
hematopoiesis is conserved between humans and zebrafish (43), several aspects known for 
human megakaryopoiesis including MK endomitosis and proplatelet formation with loss of the 
nucleus, are not present in zebrafish (44). At 3 dpf, embryos develop high and low GFP 
(CD41+) positive cells in the CHT tail region that consists of immature and mature thrombocytes 
with a nucleus, respectively. 
Another study limitation in addition to these important differences between human and 
zebrafish megakaryopoiesis is the fact that we have not yet identified members of other 
pedigrees with a similar genetic defect. However, we have shown that the profound proplatelet 
formation defect found in MKs from the affected cases can be rescued using an SRC inhibitor 
and this observation can be replicated in normal stem cells transduced with the E527K lentiviral 
vector. The definitive experiment would be to rescue the proplatelet defect in MKs differentiated 
from a patient-derived iPS line via genetic correction of E527K. 
In conclusion, our genome sequencing analysis approach based on detailed HPO 
coding, progenitor cell expression data, pathogenicity predictions and co-segregation studies 
was used to discover a germline gain-of-function variant of SRC linking the first ever discovered 
oncogene, which has been studied for decades, with a new syndrome. 
 
MATERIALS AND METHODS 
Study design 
The overall objective of this study was to identify and characterise the genetic defect causing 
thrombocytopenia, bleeding and myelofibrosis in affected cases of the presented pedigree. A 
variant encoding E527K in SRC arose as a primary candidate. Subsequent studies were 
performed to identify the defective pathway, analyse the platelet and MK defect using patients’ 
cells, replicate the phenotypes using lentiviral transduced stem cells and a zebrafish model and 
apply a rescue strategy using SRC inhibitor-1. Platelet and MK defects were studied in patients 
with (cases 31 and 35) and without (case 19) signs of myelofibrosis. The following experiments 
were performed blinded: quantification of proplatelet formation using lentiviral transduced stem 
cells and the quantification of bone length and area for all zebrafish experiments. All data are 
included (no outlier values were excluded). 
 
HPO node abbreviations 
Abdom. Orgs.: Abdominal organs; AG: Abnormal α-granules; AGD: Abnormal α-granule 
distribution; BBFT: Abnormality of blood and blood-forming tissues; BMT: Bleeding with minor or 
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no trauma; Endo.: Endocrine; Gen.: Genitourinary; IMPV: Increased mean platelet volume; 
MCLBM: Abnormality of multiple cell lineages in the bone marrow; Min.: Mineral; Morph.: 
Morphology; NAG: Abnormal number of α-granules; OCS: Abnormal surface-connected open 
canalicular system; PA: Phenotypic abnormality; Plt(s): Platelet(s); Recur. Frac.: Recurrent 
fractures; Skel.: Skeletal; Subcut. Hem.: Subcutaneous hemorrhage; Sys.: System; TCP: 
Thrombocytopenia. Certain term definitions have been shortened for conciseness (e.g. 
"Abnormality of the teeth" is shown as "Teeth"). 
 
Case information and informed consent 
Clinical information of the pedigree is reported in Fig. 1A and Table 1.  Pedigree members 
signed informed consent to participate in the BRIDGE-BPD study and the enhanced clinical and 
laboratory phenotyping studies. The Ethics Committee of the University Hospital Leuven 
approved the study (ref. ML3580). Cases enrolled to the BRIDGE-BPD (UK REC10/H0304/66) 
and to the NIHR BioResource-Rare Diseases (UK REC 13/EE/0325)/BPD studies after 
providing informed written consent. 
 
DNA extraction, sequencing and variant calling 
Genomic DNA was isolated from venous blood or saliva obtained from cases at enrolment or 
retrieved from the sample archive.  Extracted DNA was quality controlled by gel electrophoresis 
and by three independent measurements of DNA concentration, namely Picogreen (Life 
Technologies Ltd), Qubit (Life Technologies) and Glomax (Promega). Whole exome sequencing 
(WES) for DNA samples in BRIDGE was performed as described previously (15). Whole 
genome sequencing (WGS) libraries were prepared using a TruSeq DNA PCR-free protocol and 
sequenced in 125 bp paired-end reads by Illumina Cambridge Inc. such that 95% of the 
GRCh37 reference genome had a read coverage of at least 15X. The G to A variant at position 
36,031,750 of chromosome 20 was confirmed by Sanger sequencing (StarSEQ) using PCR-
amplified fragments (F-cccactttcctcaccggagcc and R-ctcgcccctggcaattcagccc). 
 
Variant annotation and filtering 
A multi-sample VCF was annotated with allele frequencies from ExAC release 0.2 containing 
genotypes for up to 61,486 samples. CADD scores and functional impact with respect to 
Ensembl 70 were obtained using snpEff (45). Variants with a frequency greater than 0.001 in 
ExAC were removed by filtering. The allele frequency threshold for removing variants in our in-
house collection of 2,974 subjects was set to 0.01. 
 
Literature-based gene prioritisation 
In order to obtain the ranking by phenotypic relevance of the 67 candidate variants, we 
constructed HPO profiles for each of the corresponding genes and computed the mean 
phenotypic similarity (46) of cases 13, 31 and 35 to those profiles. The phenotypic similarity 
used information content assigned to each term derived from 856 unrelated individuals with 
inherited BPDs of unknown molecular etiology in the BRIDGE study. The profiles were 
constructed by combining HPO terms associated with each gene (whereby they were assigned 
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terms associated with diseases (46) linked to the gene through OMIM) and HPO terms derived 
from mapping MPO terms associated with corresponding mouse models (47) through the cross-
species ontology Uberpheno (48). Terms from OMIM and/or MPO were available for 31 of the 
67 candidate genes. 
  
Identification of genes specifically overexpressed in megakaryocytes 
We used the MMSEQ (49) expression estimates from the Blueprint Consortium progenitors 
dataset (20) to perform a comparison of nine different models using MMDIFF (50). We 
compared a baseline model with single mean across all cell types, to which we assigned a prior 
probability of 0.5, with eight alternative models in which the mean for one cell type was 
assumed to differ from the mean for all other cell types combined. We assigned a prior 
probability of 1/16 to each of the alternative specific models. The probability of the model 
postulating a megakaryocyte (MK)-specific mean expression level was multiplied by the sign of 
the fold change between the MK samples and the other samples in order to rank genes by their 
probability of being overexpressed specifically in MKs. 
 
Probability of segregation between genotype and phenotype 
Assuming that a single founder introduced the rare variant into the pedigree, the probability of 
the genotypes (obtained by Sanger sequencing) of additional members of the pedigree given 
the pedigree structure and the initial genotyping results (called by high-throughput sequencing) 
under the null hypothesis that the variant is not in linkage with the phenotype is given by 
 ( | )   =
 
 (   |     = 1, ) (   = 1| ), 
where the random variable    = 1 if subject   has a copy of the mutant allele as verified by 
Sanger sequencing and 0 otherwise;    = 1 if subject   has a copy of the mutant allele as 
verified initially by WES/WGS and 0 otherwise; and    = 1 if and only if subject   is a founder 
and introduced the variant into the pedigree. We derive the probability of the co-segregation 
results in the pedigree under the null of no linkage as 2 ⋅ (1
2
)5(1
2
) = 0.03125, given    = 1 if 
  ∈ {19,23,25},    = 0 if    = 21 and    is unknown otherwise;    = 1 if   ∈ {13,31} and    = 0 
otherwise. 
 
Reagents 
The following antibodies were used: rabbit antibodies against total (pan), Y419 and Y530 forms 
of SRC (all from Life Technologies), rabbit antibody SRC that cross-reacts with Zebrafish (2108, 
Cell Signaling), tyrosine phosphorylation antibody 4G10 (Millipore), rabbit antibody for Cortactin 
(H222, Cell Signaling), phalloidin-rhodamine for F-actin (Sigma) and mouse monoclonal against 
GAPDH (clone 4G5; Fitzgerald Industries International). SRC inhibitor-1 (Sigma) was used at 
500 nM final concentration for all experiments except that 2 µM was added to zebrafish water.  
 
Functional and morphological platelet studies 
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EDTA anticoagulated blood was analyzed on an automated full blood cell analyser to determine 
blood cell counts and other red cell indices. Platelet-rich plasma (PRP) was prepared by 
centrifugation (15 minutes at 150g) of whole blood anticoagulated with 3.8% trisodium citrate 
(9:1). PRP was used for functional studies and EM, as described (51). Briefly, aggregation 
studies were carried out by adding Horm collagen, ristocetin, TRAP6, arachidonic acid, U46619 
and ADP at the indicated concentrations (Table 1). ATP secretion tests were performed after 
stimulation of platelets with Horm collagen. The expression of P-selectin (CD62P) on the 
platelet outer-membrane was measured by flow cytometry as described under basal and 
activated conditions with Horm collagen and convulxin (52). We used the Cell Diva software for 
two-color immunofluorescence acquisition on a FACS Canto II flow cytometer (BD Biosciences) 
and FlowJo software for analysis and presentation (Tree Star Inc). See below for details of the 
statistical analysis. 
 
Western blot of total platelet lysates for α-granule markers 
Protein lysates were obtained from platelets as described previously (51). Protein fractions were 
resolved by SDS/PAGE and blots were incubated with the following rabbit polyclonal antibodies: 
homemade anti-Tsp1 (53), anti-Vwf-HRP (Dako) and anti-integrin β3 (Itgb3) antibody (H-96) 
(Santa Cruz Biotechnology). Membranes were next incubated with HRP-conjugated secondary 
antibody and staining was performed with the ECL detection reagent (Life Technologies). 
Chemiluminescent blots were imaged with the ChemiDoc MP imager and the ImageLab 
software version 4.1 (Bio-Rad) was used for image acquisition. Unaltered blots are included in 
fig. S16-20. 
 
Western blot of basal and collagen-activated washed platelets for SRC quantification 
To obtain washed platelets, PRP from citrate anticoagulated blood was diluted with 2 volumes 
of acid-citrate-dextrose (ACD) supplemented with prostaglandin E1 (Pfizer) at final 
concentration of 1 µg/ml. After centrifugation, platelets were resuspended in Tyrode-HEPES 
buffer (10 mM HEPES [pH 7.5], 12 mM NaHCO3, 137 mM NaCl, 2.7 mM KCl, 5 mM glucose, 1 
MgCl) and the concentration was adjusted to 250 x 103 platelet/µL and supplemented with a 
pharmaceutical blocking compound of αIIbβ3 (Itga2b/Itgb3) (1/100 of Integrilin, Millennium 
Pharmaceuticals). Washed platelets (300 µL) were activated with 2 µg/ml Horm collagen or 10 
µM ADP for different time intervals without stirring, centrifuged and the pellet was dissolved in 
100 µL SDS-phospho loading buffer supplemented with protease inhibitors, 2mM NaF and 2mM 
NaVO3. Gels were loaded with 5 µL for each condition. Chemiluminescent blots were imaged 
with the ChemiDoc MP imager (Bio-Rad) and the ImageLab software version 4.1 was used for 
image acquisition and densitometric analysis. Statistical analysis is described in the 
supplementary materials. Unaltered blots are included in fig. S16-20. 
 
SRC kinase assay 
The complete coding region of wild-type (E527) and mutant (527K) SRC was cloned as a GST-
tagged construct in the pGEX-4T-2 vector (GE Healthcare Biosciences, Pittsburgh, PA, USA). 
Purified GST-SRC proteins using glutathione sepharose beads were used in combination with 
 13 
 
the HTScan SRC kinase assay kit (Cell Signaling Technology) using the colorimetric ELISA 
approach as described by the manufacturer (54).  
 
Cloning, COS-7 transfections and Western blot analysis 
Wild-type and mutant SRC was cloned as a Myc-tagged construct in the pSecTag2 vector (Life 
Technologies). COS-7 cells were transfected with jetPRIME DNA and siRNA transfection 
reagent according to the manufacturer's instructions (Polyplus Transfection). Cells were lysed 
48 hours after transfection in SDS-phospho buffer and SRC and GAPDH blots were done as 
described for washed platelets. Transfections and all blots were done in triplicate using 2µg 
E527, 527K or empty vector (V) or a combination of 1µg E527 with 1µg 527K. Unaltered blots 
are included in fig. S16-20. 
 
Thrombopoietin measurement 
TPO levels were determined in citrated plasma using a commercially available kit (R & D 
Systems Inc.). 
 
Colony assays 
CD34+ HSCs were isolated from peripheral blood from case 31 and an unrelated healthy control 
by magnetic cell sorting (Miltenyi Biotec) and colonies were grown as described (55, 56). 
Briefly, CD34+ cells (1 x 104 and 1 x 103; respectively for MK and GEMM) were cultured in 
triplicate in Megacult-C 04973 (MK) and Methocult 04964 (GEMM), according to the 
manufacturer's instructions (StemCell Technologies). The total number of MK and GEMM 
colonies were counted 7 and 12 days later using a light microscope (Leica DM RBE). Colonies 
were blindly counted. 
 
Suspension megakaryocyte cultures, lentiviral transductions, proplatelet and ploidy 
analysis 
CD34+ HSCs were isolated from peripheral blood from pedigree cases 19, 21, 31 and 35 and 
three unrelated healthy controls as per above. WT and E527K SRC were cloned to replace the 
eGFP-T2A-fLuc reporter cassette in pCH-SFFV-eGFP-P2A-fluc transfer plasmid (57). The pCH-
SFFV-eGFP-P2A-fluc was used as control. Vector particles were produced and concentrated by 
the Leuven Viral Vector Core as described before (57). About 1x10e6 CD34+ cells isolated from 
unrelated normal blood buffy coats were transduced for 48 hours with these vectors and 
differentiated as described (56) to MKs. About 1 x 106 CD34+ cells isolated from unrelated 
normal blood buffy coats were transduced for 48 hours with lentiviral vectors in the presence or 
absence of SRC inhibitor. CD34+ cells were cultured in StemSpan SFEM medium with or 
without SRC inhibitor (Stemcell Technologies), supplemented with 20 ng/ml TPO, 10 ng/ml Scf, 
10 ng/ml Il-6 and 10 ng/ml Flt-3 (Peprotech) as described (56). At day 12 of culture, proplatelet 
forming MKs were counted and, for immunostaining experiments, MKs were placed overnight 
on fibrinogen-coated coverslips at different days of culture (8, 12 and 13). Stainings were 
photographed at 63x magnification with a Zeiss Axiovert microscope and captured with Zeiss 
Axiovision. Ploidy analysis was performed at day 12 by flow cytometry as described (56). 
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Functional genetics in zebrafish 
Tg(cd41:EGF)  (44) (gift from Dr L. Zon (Hematology Division, Brigham and Women's 
Hospital's, Boston) zebrafish embryos were injected at the 1-cell stage with a src splice 
morpholino (tgtagtctgctttacctaatatgcc), developed by Gene-Tools LLC (Philomath), or wild type 
or E525K mutant src mRNA (ENSDARG00000008107). The analysis of thrombocyte, 
erythrocyte and GATA1-positive hematopoietic stem cell formation was analysed as we 
described before (55, 58). Cartilage structures were stained at 5 dpf with alcian blue as 
described (59) and quantification of bones was performed as described (59). All animal 
protocols were approved by the Ethical Committee of the Katholieke Universiteit Leuven. 
 
Fibroblast staining 
Skin fibroblasts were grown in DMEM/F12 and passage 4 were used for immunostaining. 
Adherent fibroblasts were washed and fixed with 4% paraformaldehyde in cytoskeleton buffer 
(0.1M PIPES, 2M glycerol, 1mM EDTA, 1mM MgCl2, pH 6.9), and permeabilized for 15 minutes 
with 0.2\% triton X-100 (Roche) at room temperature. Images were performed on a Zeiss 
Axiovert 100M confocal microscope (Carl Zeiss inc.). 
 
Statistical analysis of flow cytometry and Western blot data 
Analysis of flow cytometric measurements of P-selectin (CD62P) on the outer-membrane of 
platelets, OD450 readout of the ELISA assay on bacterial cells and Western blot data from 
platelet lysates and COS-7 cells was done by fitting the linear mixed models described in 
Supplementary Materials. Regression coefficients were estimated using the lme4 R package 
(60) and associated p-values were computed using likelihood ratio tests. Statistical analysis for 
colony assays, proplatelet formation, quantification of Y419+ MKs, MK ploidy and zebrafish data 
was performed using Graphpad Prism 6. Details on sample sizes, statistical methods and p-
values are listed in table S2.  
 
SUPPLEMENTARY MATERIALS 
Supplementary Materials and Methods     
● Statistical analysis of CD62P FACS data 
● Statistical analysis of OD450 ELISA data    
● Statistical analysis of platelet Western blot data  
● Statistical analysis of COS-7 transfection Western blot data 
● Statistical analysis of COS-7 transfection Western blot data with inhibitor   
Fig. S1. Sanger sequencing chromatograms 
Fig. S2. Electron microscopy images 
Fig. S3. Representative histograms of CD62P release from α-granule membranes 
Fig. S4. Amino acid conservation across species and human SFKs 
Fig. S5. Protein structure of SRC 
Fig. S6. Antiphosphotyrosine immunoblots 
Fig. S7. Immunoblot analysis of FGR, YES and FYN 
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Fig. S8. Immunoblot analysis of MPL 
Fig. S9. Images of skin fibroblasts stained with phalloidin-rhodamine and anti-SRC-Y419 
Fig. S10. Megakaryocyte ploidy analysis by flow cytometry 
Fig S11. Proplatelet analysis of differentiated fibrinogen-adhered lentiviral-transduced MKs 
Fig. S12. Immunofluorescence confocal microscopy images of differentiated fibrinogen-adhered 
lentiviral-transduced MKs 
Fig. S13. Quantification of podosomes in differentiated fibrinogen-adhered lentiviral-transduced 
MKs 
Fig. S14. Hematopoiesis analysis of zebrafish embryos 
Fig. S15. Thrombocyte and bone analysis of zebrafish embryos  
Fig. S16-S20. Unaltered western blots 
Table S1. Probability of over-expression of SFK members in MKs relative to other progenitor 
cells.  
Table S2. Statistical data. 
Table S3. Additional BRIDGE-BPD Consortium members. 
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TABLES 
Table 1. Clinical phenotype and blood and bone marrow analysis results of four affected 
cases (13, 19, 31 and 35) and unaffected case 21 with enhanced assessment. 
 
FIGURES 
Fig. 1. Selection of the c.1579G>A mutation in SRC as a candidate pathogenic variant. (A) 
Pedigree showing male (square) and female (circle) members who have 
macrothrombocytopenia (blue), are unaffected (empty) or are without clinical information (gray), 
some of whom are deceased (slash). Cases carry the c.1579G>A mutation in SRC (M) in 
variant calling done by whole genome sequencing (#), whole exome sequencing (✱) and/or 
Sanger sequencing (all genotyped subjects). (B) Barplot showing the mean phenotypic 
similarity of cases 13, 31 and 35 to OMIM/MPO phenotypes associated with each gene, 
truncated at the top 20 genes, with novel variants absent from control data indicated by * and 
SRC highlighted in blue (as in (D) and (E)). (C) The numbers inside each node indicate which 
cases were coded with the corresponding HPO term. Terms in green are also present in the 
OMIM/MPO entries for SRC/Src. The size of each node is determined by its contribution to the 
mean phenotype similarity score between the three cases and the OMIM/MPO terms for 
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SRC/Src. See materials and methods for abbreviations. The cases of this pedigree were the 
only ones enrolled in the BRIDGE Bleeding and Platelet Disorders study coded with 
“Thrombocytopenia”, “Myelofibrosis” and “Abnormality of the skeletal system”. (D) Barplot 
showing the CADD phred score of the rare variant for each candidate gene. (E) The probability 
that each candidate gene is specifically over-expressed in MKs compared to blood stem cells 
and six other hematopoietic progenitors.  
 
Fig. 2. Platelet phenotype related to SRC E527K gain-of-function mutation. (A) Blood 
smears from cases 31, 35 and 19 showing large platelets with a grayish appearance (black 
arrows). EM images of platelets for the three cases show (i) round platelets that rarely have a 
normal discoid shape, (ii) some dysmorphic platelets (DP), (iii) platelets with many open 
canalicular system (OCS)-forming vacuoles, (iv) a reduced level of microtubules (MT), (v) a 
reduced number of α-granules with a subpopulation of platelets exhibiting small granules (SG) 
or a near absence of all types of granules, reduced levels of internal membranes and a 
cytoplasm that appears amorphous. Horizontal bars indicate 1µm. See fig. S2 for EM images of 
normal platelets. (B,C) The platelet area and number of total alpha granules/platelet were 
quantified. Values are the mean and s.e.m as quantified for 50 randomly selected platelets for a 
healthy control (C) and cases 31, 35 and 19. One-way ANOVA with Bonferroni's multiple test. 
****p<0.0001 (D) Western blot shows Vwf, Tsp1 and β3 integrin (ITGB as loading control) 
expression for platelets from a healthy control (C) and cases 31, 35 and 19. (E) Left panel. 
Flow cytometric analysis of P-selectin (CD62P) on the outer-membrane of platelets from case 
35 (blue) and an unrelated healthy control (red, WT) after activation with collagen. Right panel. 
Summarised mean fluorescence intensities (MFI) for two healthy controls (red) and cases 19, 
31 and 35 (blue) (see Supplementary Materials for analysis and fig. S3 for representative image 
of convulxin activation). (F) Crystallography-based models of the SRC structures show the 
interaction of the C-terminal regulatory tail with SH2 domain residues (fig. S5). Left panel. 
Zoom-in of the surroundings of the atomic environment of phosphorylated (P)-Y530 in wild-type 
SRC. Residues 158, 159, 178 and 181 of the SH2 domain involved in the interaction with 
residues 520, 521, 527 and 530 of the kinase domain (Velcro-strap) are in stick mode. 
Electrostatic interactions are shown with orange dotted lines and the temperature factor of the 
Velcro-strap is shown with a blue to red gradient (from lower and higher flexibility, respectively). 
Right panel. Similar structure for the SRC-K527 mutant protein but note the reduced predicted 
flexibility of the Velcro-strap (residues are blue) leading to a rearrangement between the Velcro-
strap and SH2 domain. (G) Left panel. SRC kinase activity was measured with a colorimetric 
ELISA assay using different concentrations of ATP. The optical density at 450 nm (OD450) was 
measured for GST-tagged wild type (GST-WT) and E527K (GST-527K) SRC protein with and 
without the addition of the SRC inhibitor. Right panel. Total (Pan), active (Y419) and inactive 
(Y530) SRC protein levels were assayed via immunoblot analysis of GST-WT and GST-527K 
fusion proteins used for the kinase assay.  
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Fig. 3. SRC expression studies in platelets and transfected COS-7 cells. (A) Triplicate 
western blots for total (Pan), active (Y419) and inactive (Y530) SRC were performed for platelet 
lysates obtained from non-stimulated and collagen-stimulated platelets for 30, 60 and 300 
seconds for 2 controls and 3 cases (19, 31 and 35). Left panel. All blots were quantified and 
we fitted a linear mixed model to the log normalized mean pixel intensity (MPI) data of the SRC 
protein levels in platelets for carriers of the wild-type or mutant allele. The residuals after 
adjusting for genotype and antibody fixed effects are shown for the Y419- and Y530-targeting 
antibodies. Right panel. Representative blot. GAPDH was used as normalisation control. The 
unaffected case 21 has normal levels of total, active and inactive SRC in non-stimulated 
platelets. (B) Immunoblot analysis showing whole-platelet tyrosine phosphorylation (4G10 
antibody) stimulated by collagen or ADP from 30 to 300 seconds in platelets from a control and 
cases 35 and 19. The same platelet lysates were used as above. (C) Western blots were 
performed for lysates obtained from COS-7 cells transfected with empty (V), SRC wild-type 
(WT) and SRC-K527 vectors from a triplicate transfection experiment. Left panel. Residuals 
obtained after fitting a model without an interaction term between presence of the mutant allele 
and the level of binding of anti-Y530 antibody. Such a term is required to obtain a good model 
fit due to the dramatic decrease of Y530 in cells carrying the mutant rather than the WT allele 
(see supplementary materials). Right panel. Representative blot. (D) Western blots were 
performed for lysates obtained from COS-7 cells transfected with the same SRC vectors as in 
(C) with or without addition of SRC inhibitor-1 (inh) in a triplicate transfection experiment. Left 
panel. Residuals obtained after fitting a model without a fixed inhibitor term. Such a term is 
required to obtain a good model fit (see supplementary materials). Right panel. Representative 
blot. 
  
Fig. 4. Effect of the SRC E527K gain-of-function mutation on megakaryopoiesis. (A) 
Plasma TPO levels (pg/ml) and platelet count (PLT) (x 109/L) for a patient with proven 
congenital amegakaryocytic thrombocytopenia (CAMT) (black square), three SRC cases (blue 
symbols) and five unrelated healthy controls (red circles). The assay sensitivity limit is 25 pg/ml 
(indicated by red line). Squares and circles in blue represent samples collected in 2004 and 
2014, respectively for SRC cases . (B) Total amount of CFU-MK (upper panel) and CFU-GEMM 
(lower panel) colonies derived from peripheral blood CD34+ mononuclear cells from a control 
(C1) and case 31 counted at days 7 and 12 of culture. Values are the mean and s.e.m as 
quantified for a triplicate plating experiment. One-way ANOVA with Bonferroni's multiple test. 
Upper panel Day 7 **p=0.0059, Day 12 ***p=0.0006 Lower panel Day 7 **p=0.0015, Day 
12**p=0.0048.  (C) Left panel. Representative light microscopy images of cultured MK showing 
formation of proplatelet extensions (white arrows) for the controls (C1 and C2). Proplatelet 
forming MKs are almost absent for the cases. Scale bars, 20 µm. Right panel. Proplatelet 
formation was quantified in MK suspension triplicated liquid cultures (for each condition) 
performed on two separate occasions (firstly, two controls and three cases and, secondly, a 
control, case 31 and unaffected case 21 with and without SRC inhibitor-1). The proportion of 
proplatelet formation was lower in the cultures from cases compared to controls but normal for 
the unaffected case. Addition of the inhibitor resulted in a rescue of the proplatelet formation 
 23 
 
defect. Values are the mean and s.e.m as counted for MKs present in 10 randomly selected 
slides for each condition. One-way ANOVA with Bonferroni's correction. ****p<0.0001, 
*p=0.049. (D) Representative immunofluorescence confocal microscopy images of 
differentiated fibrinogen-adhered MKs at day 12 of culture visualised for active SRC (green, 
Y419) and DAPI (blue), showing rosette-like structures in MKs from case 31 while control MK 
(C3) only stained weakly positive for active SRC. Scale bars, 5 µm. Quantification of MKs 
positive for active SRC staining showed a significant difference between controls and cases. 
Values are the mean and s.e.m as counted for 10 randomly selected images for each condition. 
t-test. p = 0.0003 (E) Western blots for total (Pan), active (Y419), inactive (Y530) SRC, GFP 
and overall tyrosine phosphorylation (4G10) were performed for lentiviral-transduced cells 
differentiated for 12 days to MKs. GFP only generates a signal for the control vector. WT-
transduced cells overexpress inactive SRC while E527K-transduced cells express active SRC. 
The overexpression of SRC in WT and E527K-transduced cells is also visible in the 4G10 blots 
though E527K-transduced MKs also display increased tyrosine phosphorylation of other 
proteins. (F) Quantification of the ploidy analysis of two independent transduction experiments 
showed a significant left shift for E527K transduced MKs (blue) indicative of more immature 
diploid (2N DNA) MKs compared to WT (red). Two-way ANOVA. For the interaction between 
ploidy and genotype ****p<0.0001 (G) Proplatelet formation was quantified in MK suspension 
cultures from a duplicated transduction experiment in a blinded fashion. The proportion of 
proplatelet formation was lower in the cultures from E527K transduced cells compared to WT 
conditions. Values are the mean and s.e.m as counted for MKs present in 10 randomly selected 
slides for each condition. One-way ANOVA with Bonferroni's correction. For both WT-1 vs 
E527K-1 and WT-2 vs E527K-2: ****p<0.0001. (H) Immunofluorescence confocal microscopy 
images of differentiated fibrinogen-adhered and lentiviral-transduced MKs at day 12 of culture 
visualised for active SRC (green, Y419) and phalloidin (red, F-actin), showing co-localisation in 
MKs from E527K-transduced MKs but not in WT-transduced cells.  Scale bars, 20 µm.  
 
Fig. 5. Phenotype analysis of zebrafish injected with buffer (C), src-E525K or src-WT 
mRNA in the absence or presence of the SRC inhibitor-1 (inh). (A) Left panel. 
Stereomicroscope images of the caudal hematopoietic tissue (CHT) region in the tail at 3 dpf to 
visualize the GFP-labeled thrombocytes using Tg(cd41:EGFP) zebrafish. Middle panel. 
Immunoblot analysis of 15 lysed embryos at 3 dpf for expression of total Src, GFP and total 
tyrosine phosphorylation using 4G10 antibody. Right panel. Blot quantification of a triplicate 
injection experiment showed a trend for reduced GFP levels for E525K injected embryos that is 
corrected when the inhibitor is added to the fish water. (B) Alcian blue cartilage staining at 5dpf 
showing cartilage defects in src-E525K overexpression embryos that can be rescued by SRC 
inhibition. pq, palatoquadrate; mc, Meckel's cartilage; cb, ceratobranchials; cl, cranial length as 
specified in fig. S15. Left panel. Representative images. Middle panel. Graph of length ratio of 
pq, mc and cb cartilages standardized by cranial length. Right panel. Graph of area ratio of pq, 
mc and cb cartilages standardized by cranial length. Values are the mean and s.e.m as 
quantified for 6 randomly selected embryos for each condition. One-way ANOVA with 
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Bonferroni's correction. Length: ***p=0.0002, ****p<0.0001 and *p=0.0196. Area: ****p<0.0001, 
***p=0.0006  
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ID Age bracket (yrs) Blood smear examination Bleeding symptoms Bone marrow biopsy Other phenotypes
2004
PLT RBC HGB WBC ATP secretion
10-9/l 10-12/l g/dl 10-9/l Collagen ADP Collagen TRAP U46 AA Risto
N: 150-450 N: 3.9-5.3 N: 11.5-13.5 N: 5.5-15.5 2 μg/ml 5 μM 2 and 1 μg/ml 15 μM 1.3 μg/ml 1mM 1.2 mg/ml
33 3.5 8.9 8.7 WBC: normal.
_ _ _ _
RBC: aniso- and poikilo-cytosis with
hypochro-masia.
PLT: large and agranular platelets.
124 4.7 12.6 8.3 WBC: normal.
188 4.0 12.1 7.4 RBC: normal.
PLT: majority normal, but some
large and hypo- or a-granular
(“gray”) ones (10% gray platelets).
81 4.0 10.9 14.1
WBC: normal, except large granular
lymphocytes.
51 3.5 9.9 11.1
RBC: aniso- and poikilo-cytosis with
hypochro-masia. Nucleated target
cells, spherocytes, acanthocytes,
microcytes, basophilic stippling,
Howell-Jolly bodies and teardrop
cells.
PLT: anisocytosis with some large
hypo- or a- granular ones (20 %
gray platelets).
55 5.1 12.0 7.6 WBC: normal, except mildneutrophilia.
88 3.2 10.6 15.5
RBC: poikilocy-tosis with teardrop
cells, some hypochromic microcytic
cells .
PLT: majority normal, but some
large and hypo- or a-granular ones
(> 30% gray platelets) .
21§ 36-40 360 4.2 12.4 10.3 ND ND ND ND ND ND ND ND No bleeding
symptoms
ND No obvious clinical
phenotype
Table 1. Clinical phenotype and blood and bone marrow analysis results of four affected cases (13, 19, 31 and 35) and non-affected case 21 with enhanced assessment.
Automated full blood count analysis Platelet function tests
2004
2014
Aggregation
13* 50-55 ND ND ND ND ND ND ND Epistaxis, severe
anemia because of
colorectal cancer.
Myelofibrosis diagnosed at 22 years.
No recent biopsies.
Severe osteoporosis.
Colorectal cancer (at 51
years). Splenectomy.
19§ 36-40 N N Delayed with
pronounced
shape change
but normal
amplitude.
N N N N Epistaxis, petechiae,
severe bleeding after
tooth extraction,
menorrhagia, blood
transfusion after
delivery.
ND Facial dysmorphism,
premature edentulism,
osteoporosis.
31 30-35 NF NF NF NF NF NF NF Epistaxis, petechiae,
small hematomas.
Biopsy taken at 35 years. Reticulin
staining: grade 2/3 fibrosis. Increased
cellularity (>80%).
Facial dysmorphism,
premature edentulism,
unexplained fractures,
splenectomy at age 7
years.
35 16-20 N N Delayed with
pronounced
shape change
but normal
amplitude.
N N N N Epistaxis, petechiae,
menorrhagia, severe
bleeding after tooth
extraction.
Biopsies taken at 17, 22 and 26 years.
Reticulin staining: grade 2 to 2/3
fibrosis. Increased cellularity (90,80 and
80%). Dysmegakaryopoiesis: elevated
megakaryocyte numbers with
monolobular and hypolobular
morphology. Dyserythropoiesis:
presence of megablastoid changes,
nuclear budding, karyorrhexis and
basophilic stippling. M/E ratio of +4.8
(normal: 1.4-3.6). Right shifted myeloid
lineage  with more granulocytes that
include 61.5% neutrophils (23.4-45),
0.5% basophils (0-0.4) and 5%
monocytes (0.0-2.6). Normal amount of
CD34+ cells. Screening for JAK2, CALR
and MPL variants and karyotype
analysis were negative.
Facial dysmorphism,
premature edentulism.
N, normal; NF, Not feasible because of low platelet count; ND, not determined; ID, Rank number in pedigree tree, see Fig. 1a. PLT, platelets; RBC, Red Blood Cells; HGB, hemoglobin; WBC, White Blood Cells; TRAP, thrombin receptor activating peptide; AA, Arachidonic Acid; Risto, Ristocetin.
* Case 13 could not be recalled in 2014 for further phenotyping because she was undergoing chemotherapy treatment for colorectal cancer.
§ Case 19 had a mean platelet volume (MPV) of 10.5 and 8.5 fl in 2004 and 2014, respectively; MPV could not be measured reliably for other cases because of the abnormal morphology of the platelets. Case 21 has a MPV 8.8 fL.
